Skye Bioscience Inc.(US:SKYE) Prnewswire·2025-10-08 21:45Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On October 6, 2025, Skye announced that its Phase 2a study of nimacimab did not meet its primary endpoint of weight loss compared to placebo, leading to a significant drop in stock price [1] Company Overview - Skye Bioscience, Inc. is a publicly traded company on NASDAQ under the ticker SKYE [1] - The company is involved in the development of nimacimab, a peripherally-restricted CB1 inhibitor antibody [1] Financial Impact - Following the announcement of the study results, Skye's stock price fell by $2.85 per share, representing a 60% decrease, closing at $1.90 per share on October 6, 2025 [1]